Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

17.56 -0.01 (-0.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 Next >
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Clarifies Details of Recent S-3 Filing
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces $65 Million Private Placement
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium
From Pulse Biosciences
Via Business Wire
Pulse Biosciences Reports Third Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Second Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.